PMID- 35773101
OWN - NLM
STAT- MEDLINE
DCOM- 20221122
LR  - 20221130
IS  - 1095-9157 (Electronic)
IS  - 0896-8411 (Linking)
VI  - 132
DP  - 2022 Oct
TI  - Dendritic cells in systemic lupus erythematosus: From pathogenesis to therapeutic 
      applications.
PG  - 102856
LID - S0896-8411(22)00064-6 [pii]
LID - 10.1016/j.jaut.2022.102856 [doi]
AB  - Systemic lupus erythematosus (SLE) is a severe chronic systemic autoimmune 
      disease caused by complicated interactions among genetic, epigenetic, and 
      immunological factors. Dendritic cells (DCs), as the most important 
      antigen-presenting cells, play pivotal roles in both triggering pathogenic 
      autoimmune responses, and also maintaining immune tolerance. Distinct DC subsets 
      are endowed with diversified phenotypic and functional characteristics, and play 
      variable roles in shaping immunity and tolerance during the development of SLE. 
      Abnormal activation or disabled tolerance of DCs not only triggers aberrant 
      production of inflammatory mediators and type I interferons leading to pathogenic 
      innate immunity and autoinflammation, but also causes an imbalance of effector 
      versus regulatory T cell responses and sustained production of auto-antibodies 
      from B cells, leading to continuously amplified autoimmune pathogenesis in SLE. 
      Over the past decade, significant progress has been made in revealing the changes 
      of DC accumulation or function in SLE, and how the functional dysregulations of 
      DCs contribute to the pathological inflammation of SLE, leading to breakthroughs 
      in DC-based therapeutics in the treatment of SLE. In this review, we review the 
      recent advances in the activation and function of the major DC subsets in the 
      pathogenesis of SLE as well as the therapeutic potential of targeting DC subset 
      or status against SLE.
CI  - Copyright (c) 2022. Published by Elsevier Ltd.
FAU - Liu, Juan
AU  - Liu J
AD  - National Key Laboratory of Medical Immunology, Institute of Immunology, Second 
      Military Medical University, Shanghai, 200433, China. Electronic address: 
      juanliu@immunol.org.
FAU - Zhang, Xiaomin
AU  - Zhang X
AD  - National Key Laboratory of Medical Immunology, Institute of Immunology, Second 
      Military Medical University, Shanghai, 200433, China.
FAU - Cao, Xuetao
AU  - Cao X
AD  - National Key Laboratory of Medical Immunology, Institute of Immunology, Second 
      Military Medical University, Shanghai, 200433, China; Department of Immunology, 
      Institute of Basic Medical Sciences, Chinese Academy of Medical Sciences, 
      Beijing, 100005, China; Frontier Research Center for Cell Response, Institute of 
      Immunology, College of Life Sciences, Nankai University, Tianjin, 300071, China. 
      Electronic address: caoxt@immunol.org.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20220627
PL  - England
TA  - J Autoimmun
JT  - Journal of autoimmunity
JID - 8812164
RN  - 0 (Interferon Type I)
SB  - IM
MH  - Humans
MH  - Dendritic Cells
MH  - *Lupus Erythematosus, Systemic/etiology/therapy
MH  - *Interferon Type I
MH  - Immune Tolerance
MH  - B-Lymphocytes/pathology
OTO - NOTNLM
OT  - Dendritic cells
OT  - Immune pathogenesis
OT  - Immune therapy
OT  - Systemic lupus erythematosus
OT  - Type I interferons
COIS- Declaration of competing interest The authors declare no conflicts of interest.
EDAT- 2022/07/01 06:00
MHDA- 2022/11/23 06:00
CRDT- 2022/06/30 22:05
PHST- 2022/06/09 00:00 [received]
PHST- 2022/06/15 00:00 [accepted]
PHST- 2022/07/01 06:00 [pubmed]
PHST- 2022/11/23 06:00 [medline]
PHST- 2022/06/30 22:05 [entrez]
AID - S0896-8411(22)00064-6 [pii]
AID - 10.1016/j.jaut.2022.102856 [doi]
PST - ppublish
SO  - J Autoimmun. 2022 Oct;132:102856. doi: 10.1016/j.jaut.2022.102856. Epub 2022 Jun 
      27.